Balaji Amines, a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Specialty Chemicals, consolidated Q1 FY25 revenue stood at Rs. 393 crore as compared to Rs. 423 crore in Q4 FY24.

EBITDA stood at Rs. 74 crore and net profit stood at Rs. 46 crore. Total volumes stood at 28,071 MT for Q1 FY25 as against 27,984 MT in Q4 FY24.

For Q1 FY25: Amines volumes stood at 7,401 MT; Amines Derivatives volumes stood at 8,299 MT; and specialty chemicals volumes stood at 12,371 MT.

EBITDA for Q1 FY25 was Rs. 74 crore, as compared to Rs. 106 crore in Q4 FY24. EBITDA margin for Q1 FY25 stood at 19% as against 25% in Q4 FY24. PAT for Q1 FY25 was Rs. 46 crore as compared to Rs. 72 crore in Q4 FY24. Diluted EPS for Q1 FY25 stood at Rs. 13.36 per equity share as against Rs. 21.00 in Q4 FY24. On a standalone basis, we are a zero-debt company.

On the performance, D. Ram Reddy, Managing Director, Balaji Amines said, “During the first quarter of FY25, we achieved a 5% year-on-year increase in volume, however, our top line has been impacted by decrease in realisation led by decrease in Raw material pricing. We are actively managing these challenges and are confident in our ability to navigate through them while maintaining our profitability."

"The pharma market is showing encouraging signs of improvement, positioning us well for future growth. Although the Agro Chem market has been slow this quarter, we anticipate improvements in the upcoming quarters as market conditions stabilize. Our capital expenditure projects are progressing as planned. The commissioning of our methylamine plant is on schedule for Q3, and the Dimethyl ether project is expected to be completed by the end of this financial year. These projects are advancing as per the scheduled timelines and are set to significantly enhance our portfolio," commented Reddy.

"Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects in the fiscal year 2024-25. We remain dedicated to delivering value to our shareholders and stakeholders through strategic investments and a continued focus on operational excellence,” added Reddy.